Shares of Dr. Reddy’s
declined 7% on Monday in an otherwise strong market despite the company reporting a healthy set of numbers for the quarter, it was in-line on revenue and EBITDA fronts, but ahead on the PAT front.
The company reported revenue growth of 13.4% yoy to Rs4,029.6cr, broadly in-line with consensus estimates. Due to lower selling and other expenses, EBITDA reported 45.3% yoy growth to Rs818.9cr, in-line with estimates. EBITDA margins stood at 20.3%, 446bps expansion on yoy basis. Led by strong EBITDA growth, company reported PAT of Rs455.4cr, 67.4% yoy growth and ~9% ahead of consensus estimates.
Dr Reddys Laboratories Ltd's share price is currently at Rs2,591.10, down by Rs157 or 5.71%, from its previous close of Rs2,748.10 on the BSE.
The scrip opened at Rs2,780 and has touched a high and low of Rs2,780 and Rs2,544.20, respectively. So far, 27,14,757 (NSE+BSE) shares have been traded on the counter. The current market cap of the company is Rs45,636.58cr.